close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

XOMA Royalty Corporation - Common Stock (NQ:XOMA)

34.69 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about XOMA Royalty Corporation - Common Stock

< Previous 1 2 Next >
LAVA Therapeutics Stock Drops After Amended Deal With XOMA Royalty
As per the amended deal, LAVA shareholders will receive an initial cash payment of $1.04 per share, down from the range of $1.16 to $1.24 initially agreed upon. 
Via Stocktwits
Turnstone Biologics: A $100 Dream Collides with a $0.34 Reality
October 17, 2025 – In the volatile world of biotechnology, ambitious price targets often fuel investor speculation and market buzz. However, for Turnstone Biologics Corp. (NASDAQ: TSTN), the notion of... 
Via MarketMinute
Topics Intellectual Property Workforce
LAVA Therapeutics Stock Slips 9% Pre-Market – Here’s Why The Company Canceled Its Shareholder Meeting
Via Stocktwits
Mural Oncology To Be Acquired By Xoma Royalty
Via Stocktwits
XOMA Revenue Jumps 39% in Fiscal Q2
Via The Motley Fool
XOMA Royalty Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
 
Via Benzinga
Forecasting The Future: 5 Analyst Projections For XOMA Royalty
 
Via Benzinga
Turnstone Biologics To Merge With Biotech Royalty Aggregator XOMA, But Retail Sentiment Slumps
XOMA Royalty will acquire Turnstone for $0.34 in cash per share of Turnstone common stock plus one non-transferable contingent value right. 
Via Stocktwits
The Analyst Verdict: XOMA Royalty In The Eyes Of 4 Experts
 
Via Benzinga
A Glimpse Into The Expert Outlook On XOMA Royalty Through 4 Analysts
 
Via Benzinga
XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q2 2024
XOMA stock results show that XOMA missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base
FDA's Genetic Metabolic Diseases Advisory Committee will review Zevra Therapeutics' arimoclomol for Niemann-Pick disease type C on August 2. PDUFA decision expected by September 21. 
Via Benzinga
Demystifying XOMA: Insights From 5 Analyst Reviews
 
Via Benzinga
Peeling Back The Layers: Exploring XOMA Through Analyst Insights
 
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For XOMA
 
Via Benzinga
Recap: XOMA Q4 Earnings
 
Via Benzinga
3 Crazy Good Stocks to Buy With $500 Right Now
For investors with only a little money to spare, these three supercharged stocks represent an outrageous opportunity for future growth. 
Via InvestorPlace
XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q1 2024
XOMA stock results show that XOMA missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
XOMA Stock Earnings: XOMA Misses EPS, Misses Revenue for Q4 2023
XOMA stock results show that XOMA missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Biotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate Biopharma
XOMA acquires Kinnate Biopharma for $2.3352 per share, with potential additional cash. The acquisition is expected to close in April 2024. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  During Monday, 102 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  During Thursday, 56 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  On Friday, 57 companies reached new 52-week lows. 
Via Benzinga
Arimoclomol and Aldoxorubicin Acquisition to Bolster XOMA's Revenue Growth: Analyst
Earlier today, XOMA Corporation (NASDAQ: XOMA) acquired the royalty and milestone rights associated with two assets from LadRx Corporation: arimoclomol for Niemann-Pick disease type C, and... 
Via Benzinga
XOMA's Return On Capital Employed Insights
 
Via Benzinga
Recap: XOMA Q1 Earnings
XOMA (NASDAQ:XOMA) reported its Q1 earnings results on Tuesday, May 9, 2023 at 07:30 AM. Here's what investors need to know about the announcement. Earnings XOMA missed estimated earnings by 96.0%,... 
Via Benzinga
XOMA Earnings Perspective: Return On Capital Employed
 
Via Benzinga
XOMA's Return On Capital Employed Insights
 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  Wednesday saw 59 companies set new 52-week lows. 
Via Benzinga
XOMA: Q1 Earnings Insights
XOMA (NASDAQ:XOMA) reported its Q1 earnings results on Tuesday, May 9, 2023 at 07:30 AM. Here's what investors need to know about the announcement. Earnings XOMA missed estimated earnings by 96.0%,... 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today